Strategic planning

With this financial assistance from the Government of Quebec, the IRCM will become a key player on a Canadian scale in the field of research on rare and genetic diseases in adults, as well as in the discovery and development of biomarkers for precision medicine.

2016-2021: Two major initiatives

The IRCM’s vision is to become an international leader in the creation and transfer of knowledge in life sciences in order to contribute to improving human health. The strategy presented here was developed while bearing in mind this ambitious goal.

The IRCM’s 2016-2021 strategic plan includes two major institutional initiatives that are based on the institute’s areas of excellence and take into account promising avenues in research as well as society’s needs.

Initiative I: Research on rare and genetic diseases in adults

While there are more than 7,000 rare diseases, a total of 2.5 million Canadians are affected, including more than 500,000 people in Quebec. The IRCM is proposing to establish on its premises a Research centre on rare and genetic diseases in adults, a unique centre that will allow the Institute to position itself as a national leader. In addition to providing access to specialized care, the initiative will lead to the development of a model for clinical follow-up to ensure the transition from pediatric to adult care. Furthermore, this initiative will not only allow the institute to conduct research on rare diseases, but will become a central component of the translational research program required to better understand these diseases and, as a result, develop new treatments.

Initiative II: Biomarker discovery pipeline for precision medicine

Biomarkers track the evolution of physiological conditions in normal health and disease, being powerful diagnostic and prognostic tools for precision medicine. The biomarker discovery pipeline at the Montreal Clinical Research Institute integrates a number of leading-edge technologies for monitoring changes in biomarkers, including their amino acid modifications (PTMs and mutations), their interactions with other cellular components, and their abundance levels. The biomarker discovery pipeline team collaborates with many groups both in Canada and internationally on various biomarkers-related projects. 

Major institutional initiatives

The IRCM’s 2016-2021 strategic plan includes two major institutional initiatives that are based on the Institute’s areas of excellence and take into account promising avenues in research as well as society’s needs.

2016-2021 Strategic planning